menu
Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development
Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development
Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development

Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development

Owing to benefits,such as reduced manufacturing costs, availability of cheap and skilled labor,and a supportive regulatory landscape, biopharmaceutical developers from acrossthe globe, are increasingly outsourcing their manufacturing operations to Chinabased CMOs. Further, in order to meet the growing demand for their services,Chinese CMOs are actively consolidating / expanding their capabilities throughpartnerships and / or dedicated expansion initiatives.  

 

To order this 250+page report, which features 100+ figures and 120+ tables, please visit this link

 

The USD 2.6 billion(by 2030) financial opportunity within the China biopharmaceutical contractmanufacturing market has been analyzed across the following segments:

§ Type of Product 

  • API
  • FDF

 

§ Type of ExpressionSystem Used

  • Mammalian
  • Microbial
  • Others

 

§ Scale of Operation

  • Preclinical / Clinical
  • Commercial

 

§ Size of Manufacturer

  • Small
  • Mid-sized
  • Large / Very Large

 

§ Type of Biologic 

  • Antibody 
  • Vaccine
  • Others

 

The ChinaBiopharmaceutical Contract Manufacturing Market, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:

§ ChemPartner Biologics

§ JHL Biotech

§ JOINN Biologics

§ MabPlex

§ Mycenax Biotech

§ WuXi AppTec

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Case Study: Comparison of SmallMolecules and Large Molecules

5. Competitive Landscape

6. Company Profiles

7. Partnerships 

8. Recent Expansions

9. Clinical Trial Analysis

10. Regional Capability Analysis

11. Capacity Analysis

12. Big Pharma BiopharmaceuticalManufacturing Initiatives in China

13. Make Versus Buy Decision Making Framework

14. Market Sizing and Opportunity Analysis

 

15. COVID-19 Impact on China BiopharmaceuticalCMO Market

 

16. SWOT Analysis

 

17. Future of the China Biopharmaceutical CMOMarket

 

18. Interview Transcripts

 

19. APPENDIX 1: TABULATED DATA

 

20. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com